Belsomra Regulatory Status: US, EU, Canada, UK

How Suvorexant Works: The Orexin Blockade

Suvorexant is the first dual orexin receptor antagonist (DORA) approved for clinical use. It blocks both OX1R and OX2R receptors in the lateral hypothalamus, suppressing the wake-promoting neuropeptide signaling that keeps the brain alert [1]. This makes it mechanistically different from benzodiazepines, Z-drugs, and antihistamines.

The orexin system was discovered in 1998 by two independent groups. Orexin-A and orexin-B (also called hypocretin-1 and hypocretin-2) are produced by a small cluster of roughly 70,000 neurons in the lateral hypothalamus [2]. These neurons project widely across the cortex, brainstem, and basal forebrain. In narcolepsy type 1, loss of orexin-producing neurons causes intrusive sleep episodes, providing the biological rationale for pharmacologically blocking these same receptors in patients who cannot fall or stay asleep [3].

By targeting the orexin pathway rather than GABA-A receptors, suvorexant avoids several pharmacological liabilities associated with older hypnotics. It does not produce the same degree of respiratory depression, does not substantially alter sleep architecture in the way benzodiazepines suppress slow-wave and REM sleep, and carries a lower signal for complex sleep behaviors compared to zolpidem [1]. The drug has a half-life of approximately 12 hours, which supports both sleep-onset and sleep-maintenance efficacy but also means next-morning residual effects are possible at higher doses [4].

FDA Approval: The US Path

The FDA approved suvorexant on August 13, 2014, making it the first orexin receptor antagonist to reach the US market [4]. Merck submitted its New Drug Application based on a clinical program that enrolled over 3,000 patients across multiple Phase III trials.

The key trial by Herring et al., published in The Lancet Neurology in 2014, randomized 3,021 patients with primary insomnia to suvorexant or placebo over 3 months [1]. At the recommended doses (15 mg and 20 mg at the time of the trial), suvorexant reduced subjective time to sleep onset by approximately 8 to 10 minutes compared with placebo and increased total sleep time by roughly 16 to 25 minutes. Polysomnographic data confirmed statistically significant improvements in both latency to persistent sleep (LPS) and wake after sleep onset (WASO) [1].

The FDA's review was not without friction. Merck originally sought approval for doses up to 40 mg. The FDA's advisory committee expressed concern about next-day impairment at higher doses, including suicidal ideation signals and driving simulation performance decrements [4]. The agency approved a dose range of 5 mg to 20 mg, with 10 mg as the recommended starting dose and a maximum of 20 mg [4].

The DEA classified suvorexant as a Schedule IV controlled substance under the Controlled Substances Act, the same category as zolpidem and eszopiclone, based on abuse liability assessments showing that suvorexant at supratherapeutic doses (40 mg to 150 mg) produced subjective "drug liking" scores above placebo in recreational polydrug users [5].

EMA Withdrawal: Why Belsomra Is Not Available in Europe

Suvorexant has never been approved in the European Union. Merck submitted a marketing authorization application to the European Medicines Agency, but withdrew it in January 2015 before the Committee for Medicinal Products for Human Use (CHMP) issued a final opinion [6].

The withdrawal was procedural, not a formal rejection. Merck stated that the decision reflected "the regulatory environment in Europe" and differences in how the EMA weighted the benefit-risk profile at the proposed doses [6]. The EMA's preliminary assessment raised questions about whether the magnitude of clinical benefit (approximately 10 minutes of reduced sleep-onset latency and 16 to 25 minutes of additional total sleep time) was clinically meaningful enough to offset residual next-day somnolence at the 20 mg dose [6].

This outcome is not unique to suvorexant. European regulators have historically applied stricter clinical-significance thresholds to insomnia drugs. The EMA's 2011 guideline on medicinal products for the treatment of insomnia specifies that subjective endpoints alone are insufficient and that polysomnographic data should demonstrate improvements beyond what could be attributed to measurement variability [7]. Merck did not resubmit.

A second DORA, lemborexant (Dayvigo, Eisai), also pursued European approval and was rejected by the CHMP in 2022 on similar grounds regarding the clinical relevance of observed improvements [8]. Only in 2024 did a DORA receive EU marketing authorization, when the EMA approved daridorexant (Quviviq, Idorsia) based on data showing both objective polysomnographic and subjective patient-reported improvements that met the agency's thresholds [9].

Canada: No Marketing Authorization

Health Canada has not approved suvorexant for sale in Canada. Merck did not file a New Drug Submission with Health Canada following the EMA withdrawal, and no public record of a Canadian regulatory review exists for suvorexant [10].

Canadian physicians prescribing insomnia medications have access to the Z-drugs (zopiclone, which is the most commonly prescribed hypnotic in Canada, and zolpidem), benzodiazepines, low-dose trazodone, and doxepin. Among the DORA class, the only product with Health Canada approval is daridorexant (Quviviq), which received a Notice of Compliance in 2023 [11].

The Canadian Agency for Drugs and Technologies in Health (CADTH), now the Canada Drug Agency, reviewed daridorexant in 2023 and recommended reimbursement with conditions, noting that it is an option for adults with insomnia who have had an inadequate response to cognitive behavioral therapy for insomnia (CBT-I) [11]. Suvorexant's absence from the Canadian market means that patients and prescribers there cannot access this specific molecule, though the DORA mechanism is now represented by daridorexant.

United Kingdom: No MHRA Approval

Suvorexant is not authorized by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. Prior to Brexit, the UK followed EMA decisions, and Merck's 2015 withdrawal from the EMA process meant no approval pathway existed. Post-Brexit, the MHRA operates independently, but Merck has not submitted a standalone UK application for suvorexant [12].

UK prescribers managing insomnia rely primarily on the Z-drugs (zopiclone and zolpidem), short courses of benzodiazepines, and melatonin (Circadin, which is licensed for adults aged 55 and older). The National Institute for Health and Care Excellence (NICE) guideline NG215 on insomnia, updated in 2024, does not mention suvorexant by name but notes that orexin receptor antagonists represent a newer pharmacological class under evaluation [12].

Daridorexant (Quviviq) received MHRA marketing authorization in 2022, giving UK clinicians access to a DORA for the first time [13]. This makes suvorexant unlikely to pursue UK registration now that Merck's composition-of-matter patent has expired and generic versions are available in the US.

US Generic Availability and Current Market Position

Suvorexant's core US patent (US Patent 8,329,739) expired in April 2023. The FDA approved the first generic suvorexant (by Teva Pharmaceuticals) in late 2023, with additional generics from other manufacturers following in 2024 [14]. Brand-name Belsomra remains available but now competes on price with generic formulations.

Average wholesale price for brand Belsomra 10 mg was approximately $16 per tablet before generic entry [14]. Generic suvorexant 10 mg tablets are priced substantially lower, though out-of-pocket cost still varies by insurance formulary tier. Many commercial insurers and Medicare Part D plans have placed suvorexant on Tier 3 (preferred brand) or Tier 2 (preferred generic) depending on the formulation [14].

The American Academy of Sleep Medicine (AASM) 2023 clinical practice guideline for chronic insomnia in adults conditionally recommends suvorexant as a treatment option, based on moderate-certainty evidence [15]. The guideline panel noted that DORAs represent a reasonable alternative for patients who cannot tolerate or have not responded to CBT-I, though CBT-I remains the first-line recommendation.

"We suggest that clinicians use suvorexant as a treatment for chronic insomnia disorder in adults who desire pharmacotherapy," the AASM guideline states, rating the recommendation as conditional with moderate-quality evidence [15].

Controlled Substance Classification and Abuse Potential

In the US, suvorexant is a Schedule IV controlled substance, reflecting a recognized but relatively low abuse potential [5]. Abuse liability studies conducted during development tested supratherapeutic doses (40 mg, 80 mg, and 150 mg) in recreational sedative users. At 150 mg, suvorexant produced drug-liking visual analogue scale scores comparable to 30 mg zolpidem, but at the approved maximum dose of 20 mg, abuse-related subjective effects were minimal [5].

No other country has scheduled suvorexant because it has not been approved outside the United States. The World Health Organization's Expert Committee on Drug Dependence has not placed suvorexant under international control as of 2026 [16].

Post-marketing pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS) through 2025 show that suvorexant-related adverse event reports are dominated by somnolence, sleep paralysis, and hallucinations (hypnagogic and hypnopompic), consistent with its mechanism of suppressing orexin-mediated wakefulness [4]. Reports of dependence or withdrawal are uncommon compared with Z-drug and benzodiazepine reports in the same database.

Comparing DORAs: Suvorexant, Lemborexant, and Daridorexant

Three dual orexin receptor antagonists have reached regulatory approval in at least one major market. Their regulatory footprints differ significantly.

Suvorexant (Belsomra) is approved only in the US and Japan. Lemborexant (Dayvigo, Eisai) is approved in the US, Japan, and several Asian markets but was rejected by the EMA [8]. Daridorexant (Quviviq, Idorsia/now acquired by other entities) holds the broadest authorization: FDA-approved, EMA-approved, Health Canada-approved, and MHRA-approved [9][11][13].

The pharmacological differences among these three drugs are modest but clinically relevant. Suvorexant has the longest half-life (approximately 12 hours), lemborexant is intermediate (approximately 17 to 19 hours for the active compound plus metabolites but with faster receptor dissociation), and daridorexant has the shortest effective half-life (approximately 8 hours), which may explain its more favorable next-day functioning profile in the trials that satisfied European regulators [9][17].

In the Phase III trial by Herring et al. (N=3,021), suvorexant 20 mg reduced wake after sleep onset by 22.7 minutes versus placebo at month 1, an effect that persisted through month 3 [1]. Daridorexant 50 mg, in its key trial (N=930), reduced WASO by 22.8 minutes versus placebo at month 1, with the additional demonstration of improvement on the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ), a daytime-functioning endpoint the EMA valued [9].

The AASM 2023 guideline conditionally recommends all three DORAs, noting that head-to-head data are lacking and that selection should be guided by patient-specific factors including half-life considerations, formulary availability, and cost [15].

Safety Profile and Labeled Warnings

The FDA label for suvorexant carries several specific warnings [4]. CNS depression is the primary concern, and the label advises against use with other CNS depressants including alcohol. Patients should not drive or operate heavy machinery until they know how suvorexant affects them, particularly given the 12-hour half-life.

Sleep paralysis occurred in 2% of suvorexant-treated patients versus <1% of placebo-treated patients across the clinical development program [1][4]. Hypnagogic and hypnopompic hallucinations, consistent with the pharmacological blurring of wake-sleep transitions mediated by orexin blockade, were reported at similar rates [4].

Suicidal ideation was identified as a signal during FDA review. The label warns prescribers to assess patients for worsening depression or suicidality, though the causal relationship remains unclear given the high comorbidity between insomnia and mood disorders [4]. Dosing in patients taking moderate CYP3A4 inhibitors (diltiazem, erythromycin, fluconazole) should not exceed 5 mg, because suvorexant is primarily metabolized by CYP3A4 and concomitant use of strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) is contraindicated [4].

The recommended dose for most adults is 10 mg taken within 30 minutes of bedtime, with at least 7 hours of intended sleep remaining before planned waking [4].